We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Axxam and Lonza Announce the Signing of a License Agreement
News

Axxam and Lonza Announce the Signing of a License Agreement

Axxam and Lonza Announce the Signing of a License Agreement
News

Axxam and Lonza Announce the Signing of a License Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Axxam and Lonza Announce the Signing of a License Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lonza and Axxam announced the signing of a license agreement enabling Lonza to include Axxam’s Photina®, i-Photina® and Clytin® Photoproteins as calcium biosensors in Lonza’s broad range of Clonetics® Primary Cells.

“We are really pleased to have entered this license agreement with Lonza”, says Sabrina Corazza, responsible for Business Development at Axxam. “It allows us to further validate and exploit our proprietary technology platform on photoproteins, and to address relevant market needs.”

“Enabling customers to easily perform assays in primary cells is a critical component of our primary cell strategy”, states Leon de Bruin, Senior Product Manager in Lonza’s Drug Discovery Marketing group. “Our newly introduced Clonetics® Primary Sensors range of products allows customers to access their primary cells of choice and measure endogenous receptor activity using the same technologies and protocols that they are used to using with over-expressing cell lines.”

Clonetics® Primary Sensors build on Lonza’s transfection capability to address the widely stated desire by researchers to measure drug targets in a biologically relevant environment. Well characterized primary cells are expanded to generate a sizeable and robust cell bank. The sensor is added to the cell using Lonza’s efficient Amaxa® Nucleofector® Technology and substrate is added before the cells are frozen. The customer receives a frozen, ready to use product.
Advertisement